NEW YORK (360Dx) – The last year has seen a wave of excitement and investment into companies and research groups hoping to launch early cancer detection and screening tests that sift the blood for small fragments of cancer-associated DNA.
But considering the costs of genomic technologies, there is also much skepticism that circulating DNA is the best target for a test or series of tests to be applied to a broad population.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
